If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
63
results.
Updated on
28/10/2026 [06:45:00]
Absstract of: US20260327717A1
The invention features methods for the identification of genomic aberrations in circulating tumor cells isolated from peripheral blood. In embodiments, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
Absstract of: US20260325545A1
0000 Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
0000
Absstract of: US20260327304A1
The present disclosure provides an antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. The present disclosure also relates to a method for treating a solid tumor, multiple myeloma, or leukemia such as acute myeloid leukemia (AML) using the anti-LILRB4×CD3 bispecific antibody of the present disclosure.
Absstract of: WO2026221060A1
The present invention addresses the problem of providing a biomarker for predicting the prognosis of IDD-LPD. The prognosis of IDD-LPD is predicted by using the presence or absence of deletion of a specific region in a human chromosome or the presence or absence of a mutation in a specific human gene region as an indicator.
Absstract of: US20260325562A1
Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.
Absstract of: WO2026222428A1
The present disclosure provides CLL-1/CD33 dual-targeting chimeric antigen receptors (CARs). The CARs may comprise a VHH targeting CLL-1 and a VHH targeting CD33. The chimeric antigen receptors can be used to treat cancer, such as acute myeloid leukemia (AML).
Absstract of: US20260327334A1
The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMOD and a steroid. Such combinations may be used for the treatment of multiple myeloma.
Absstract of: US20260325633A1
At this invention I presents medication to leukemia and cancer/tumors.
Absstract of: WO2026221354A1
The present invention relates to a pharmaceutical composition for preventing or treating Bcl-2 family inhibitor-resistant acute myeloid leukemia. More specifically, the present invention may provide a pharmaceutical composition for preventing or treating cancer that has acquired resistance to a Bcl-2 family inhibitor, which is used as a conventional therapeutic agent for resistant acute myeloid leukemia, through inhibition of the expression of nucleolin and Mcl-1.
Absstract of: WO2026220363A2
Provided herein are methods of treating multiple myeloma, such as relapsed and/or refractory multiple myeloma. The methods involve administering to human patients diagnosed with multiple myeloma an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate), bortezomib, and dexamethasone; or an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate), pomalidomide, and dexamethasone. The disclosure further relates to dosing regimen modifications for the disclosed anti-BCMA antigen binding proteins in response to ocular adverse events in a subject being treated with the anti-BCMA antigen binding protein.
Absstract of: WO2026219079A1
Disclosed is use of a combination of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) and an erythroid maturation agent in rare anemias. In particular, a combination of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) and erythroid maturation agents has a synergistic effect in the treatment of rare anemias such as sickle cell disease (sickle cell anemia, SCD), β-thalassemia (β-thal), and myelodysplastic syndrome anemia (MDS anemia).
Absstract of: US20260327331A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Absstract of: AU2025269945A1
Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.
Absstract of: WO2025128434A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Absstract of: WO2026217529A1
The disclosure herein provides compositions for the treatment of cancer. In some embodiments, the method of treating cancer comprising: administering to a subject in need thereof celastrol and one or more additional agents selected from: simvastatin; fluoxetine; memantine; auranofin; colchicine; adefovir; pyrvinium; digoxin; fluvastatin; doxepin; and gemcitabine. In some embodiments, the disclosure provides compositions for the treatment of lung cancer, breast cancer, colorectal cancer, skin cancer, brain cancer, leukemia, pancreatic cancer, esophageal cancer, cervical cancer, head and neck cancer, or ovarian cancer.
Absstract of: AU2025251398A1
The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.
Absstract of: US20260315461A1
0000 The present invention relates to a compound of formula (I), or any of its pharmaceutically acceptable salt:
0000
0000 wherein R<1 >represents a halogen atom, a (C<1>-C<6>)alkyl group, a (C<3>-C<6>)cycloalkyl group, a (C<2>-C<6>)alkenyl group, a (C<1>-C<6>)alkoxy group or a (C<3>-C<6>)cycloalkoxy group, X and Y independently represent a —CH═ group, a —CR<3>═ group or a —N═ group, Z1 and Z2 independently represent a —CH<2>— group, a ═CH— group or a ═N— group and R<3 >and R<4 >independently represent a hydrogen atom or a halogen atom.
0000 It further relates to such a compound for its use as a medicament, and in particular for its use in treating and/or prevention of cancer, in particular cancer exhibiting recruitment of MDM2 to chromatin, more particularly selected from the group consisting of bone cancer, brain cancer, ovary cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, blood cancer, including acute myeloid leukemia, pancreatic cancer, prostate cancer and liposarcoma and even more particularly selected from the group consisting of skin cancer, blood cancer, for example but not limited to acute myeloid leukemia, melanoma and liposarcoma.
Absstract of: US20260315486A1
0000 The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Absstract of: US20260317835A1
0000 There are provided methods for detecting and classifying a B-cell malignancy selected from the group consisting of a B-cell lymphoma, a B-cell leukemia, and a plasma cell dyscrasia in a subject. The methods employ a tumor cell profiling algorithm to analyze single-cell RNA sequencing data obtained from a sample of, e.g., the subject's blood or bone marrow, enriched for a cell type comprising tumoral cells using a cell surface marker. This algorithm identifies one or more one or more expanded clonal cell populations and categorizes each of the one or more expanded clonal cell populations as malignant or pre-malignant tumor cell population if expression of one or more malignancy markers is detected. The one or more malignant or pre-malignant tumor cell population(s) can be analyzed using a statistical model or machine learning algorithm to classify the B-cell malignancy.
Absstract of: EP4821484A1
0001 The present disclosure relates to a composition, which can be a lyophilization preparation liquid or a lyophilized powder preparation. The composition comprises a multispecific antibody, a surfactant, a buffer system, and a stabilizer/a osmotic pressure regulator. Further disclosed are a preparation method and use of the composition, for example use in the treatment of a tumor, in particular multiple myeloma.
Absstract of: WO2025120113A1
Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).
Absstract of: WO2025122791A1
Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.
Absstract of: WO2025122985A1
Provided herein are methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine. Also provided herein are methods of inhibiting/overcoming resistance of AML to venetoclax in a subject in need thereof, and/or improving the efficacy of venetoclax in the treatment of AML in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine.
Absstract of: EP4821917A1
0001 A compound represented by formula (I) as a PCNA inhibitor, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, a preparation method therefor, an intermediate compound thereof, a pharmaceutical composition thereof and the use thereof. The PCNA inhibitor and the pharmaceutical composition comprising same can be used for treating cancers, comprising lung cancer, melanoma, colon cancer, rectal cancer, prostate cancer, ovarian cancer, leukemia, etc with PCNA overexpression.
Nº publicación: US20260306486A1 08/10/2026
Applicant:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES [US]
SLOAN KETTERING INST FOR CANCER RESEARCH [US]
BIOSPLICE THERAPEUTICS INC [US]
Memorial Sloan-Kettering Cancer Center
Memorial Hospital for Cancer and Allied Diseases
Sloan-Kettering Institute for Cancer Research
Biosplice Therapeutics, Inc.
Absstract of: US20260306486A1
The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.
BOPI
Electronic site
